Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 134.9 Billion KRW | 22.65% |
| 2022 | 109.99 Billion KRW | 8.27% |
| 2021 | 101.59 Billion KRW | 14.66% |
| 2020 | 88.6 Billion KRW | -18.3% |
| 2019 | 108.45 Billion KRW | 18.09% |
| 2018 | 91.83 Billion KRW | 9.03% |
| 2017 | 84.23 Billion KRW | 1.63% |
| 2016 | 82.88 Billion KRW | 3.57% |
| 2015 | 80.02 Billion KRW | -1.06% |
| 2014 | 80.87 Billion KRW | 8.96% |
| 2013 | 74.22 Billion KRW | -2.37% |
| 2012 | 76.02 Billion KRW | -13.31% |
| 2011 | 87.7 Billion KRW | -17.96% |
| 2010 | 106.9 Billion KRW | 8.33% |
| 2009 | 98.68 Billion KRW | 7.39% |
| 2008 | 91.89 Billion KRW | 11.4% |
| 2007 | 82.48 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 34.09 Billion KRW | 7.49% |
| 2024 Q2 | 31.59 Billion KRW | -7.34% |
| 2024 Q3 | 36.84 Billion KRW | 16.61% |
| 2023 Q3 | 32.96 Billion KRW | -20.4% |
| 2023 Q4 | 31.71 Billion KRW | -3.79% |
| 2023 Q2 | 41.41 Billion KRW | 43.79% |
| 2023 Q1 | 28.8 Billion KRW | -4.36% |
| 2023 FY | 134.9 Billion KRW | 22.65% |
| 2022 Q1 | 23.98 Billion KRW | -3.61% |
| 2022 Q3 | 29.64 Billion KRW | 12.92% |
| 2022 Q4 | 30.11 Billion KRW | 1.6% |
| 2022 FY | 109.99 Billion KRW | 8.27% |
| 2022 Q2 | 26.24 Billion KRW | 9.43% |
| 2021 Q1 | 27.79 Billion KRW | 27.57% |
| 2021 Q3 | 25.47 Billion KRW | 8.69% |
| 2021 Q4 | 24.88 Billion KRW | -2.31% |
| 2021 Q2 | 23.43 Billion KRW | -15.69% |
| 2021 FY | 101.59 Billion KRW | 14.66% |
| 2020 FY | 88.6 Billion KRW | -18.3% |
| 2020 Q2 | 22.6 Billion KRW | 2.28% |
| 2020 Q3 | 22.11 Billion KRW | -2.15% |
| 2020 Q1 | 22.09 Billion KRW | -15.47% |
| 2020 Q4 | 21.79 Billion KRW | -1.47% |
| 2019 FY | 108.45 Billion KRW | 18.09% |
| 2019 Q2 | 29.81 Billion KRW | 21.7% |
| 2019 Q3 | 27.99 Billion KRW | -6.11% |
| 2019 Q4 | 26.14 Billion KRW | -6.62% |
| 2019 Q1 | 24.49 Billion KRW | 5.42% |
| 2018 Q2 | 22.53 Billion KRW | 2.03% |
| 2018 FY | 91.83 Billion KRW | 9.03% |
| 2018 Q4 | 23.23 Billion KRW | -3.07% |
| 2018 Q3 | 23.97 Billion KRW | 6.39% |
| 2018 Q1 | 22.08 Billion KRW | 10.71% |
| 2017 Q1 | 19.11 Billion KRW | -3.22% |
| 2017 Q4 | 19.95 Billion KRW | -18.76% |
| 2017 FY | 84.23 Billion KRW | 1.63% |
| 2017 Q2 | 20.6 Billion KRW | 7.82% |
| 2017 Q3 | 24.55 Billion KRW | 19.15% |
| 2016 Q4 | 19.74 Billion KRW | -4.82% |
| 2016 FY | 82.88 Billion KRW | 3.57% |
| 2016 Q1 | 21.63 Billion KRW | 5.65% |
| 2016 Q2 | 20.74 Billion KRW | -4.1% |
| 2016 Q3 | 20.75 Billion KRW | 0.01% |
| 2015 Q4 | 20.47 Billion KRW | 11.85% |
| 2015 Q2 | 20.47 Billion KRW | -1.41% |
| 2015 Q3 | 18.3 Billion KRW | -10.56% |
| 2015 Q1 | 20.76 Billion KRW | 2.42% |
| 2015 FY | 80.02 Billion KRW | -1.06% |
| 2014 Q3 | 20.38 Billion KRW | 0.73% |
| 2014 FY | 80.87 Billion KRW | 8.96% |
| 2014 Q1 | 19.98 Billion KRW | 10.08% |
| 2014 Q4 | 20.27 Billion KRW | -0.54% |
| 2014 Q2 | 20.23 Billion KRW | 1.25% |
| 2013 FY | 74.22 Billion KRW | -2.37% |
| 2013 Q4 | 18.15 Billion KRW | -5.09% |
| 2013 Q3 | 19.13 Billion KRW | 0.68% |
| 2013 Q2 | 19 Billion KRW | 5.92% |
| 2013 Q1 | 17.93 Billion KRW | -1.8% |
| 2012 Q2 | 18.91 Billion KRW | 5.67% |
| 2012 FY | 76.02 Billion KRW | -13.31% |
| 2012 Q4 | 18.26 Billion KRW | -12.82% |
| 2012 Q3 | 20.95 Billion KRW | 10.8% |
| 2012 Q1 | 17.89 Billion KRW | 0.0% |
| 2011 Q2 | 22.3 Billion KRW | -5.31% |
| 2011 FY | 87.7 Billion KRW | -17.96% |
| 2011 Q1 | 23.55 Billion KRW | -14.57% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 20.84 Billion KRW | -6.55% |
| 2010 Q1 | 24.37 Billion KRW | -11.16% |
| 2010 FY | 106.9 Billion KRW | 8.33% |
| 2010 Q4 | 27.57 Billion KRW | -0.93% |
| 2010 Q3 | 27.83 Billion KRW | 2.62% |
| 2010 Q2 | 27.12 Billion KRW | 11.27% |
| 2009 Q2 | 25.17 Billion KRW | 9.97% |
| 2009 Q1 | 22.88 Billion KRW | -12.19% |
| 2009 Q3 | 23.18 Billion KRW | -7.88% |
| 2009 Q4 | 27.43 Billion KRW | 18.33% |
| 2009 FY | 98.68 Billion KRW | 7.39% |
| 2008 Q3 | 23.91 Billion KRW | 8.4% |
| 2008 Q4 | 26.06 Billion KRW | 8.96% |
| 2008 FY | 91.89 Billion KRW | 11.4% |
| 2008 Q1 | 19.84 Billion KRW | -7.83% |
| 2008 Q2 | 22.06 Billion KRW | 11.22% |
| 2007 FY | 82.48 Billion KRW | 0.0% |
| 2007 Q2 | 21.4 Billion KRW | 13.43% |
| 2007 Q3 | 20.69 Billion KRW | -3.31% |
| 2007 Q1 | 18.86 Billion KRW | 0.0% |
| 2007 Q4 | 21.52 Billion KRW | 4.03% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 1.676% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 88.082% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 78.869% |
| HANDOK Inc. | 522.74 Billion KRW | 74.192% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | 0.342% |
| Yuhan Corporation | 1858.98 Billion KRW | 92.743% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 79.682% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -159.667% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 90.951% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 63.591% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -52.279% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 20.439% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 39.895% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 1.676% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -72.843% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | 10.698% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -54.423% |
| JW Holdings Corporation | 928.07 Billion KRW | 85.463% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 77.543% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 91.919% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.977% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 32.622% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 25.366% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 31.29% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 81.427% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 1.676% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 91.092% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 90.191% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.977% |
| Yuhan Corporation | 1858.98 Billion KRW | 92.743% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 83.024% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 42.568% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 77.31% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.977% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 53.818% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 51.635% |
| CKD Bio Corp. | 160.35 Billion KRW | 15.867% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 74.398% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 62.64% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 41.444% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 32.622% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 84.666% |
| Boryung Corporation | 859.62 Billion KRW | 84.306% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -7.132% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 63.591% |
| JW Lifescience Corporation | 206.86 Billion KRW | 34.782% |